Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Early Phase 1

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06216938Early Phase 1Recruiting

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Role: lead

NCT04572451Phase 1Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Role: lead

NCT04493203Phase 2Completed

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Role: lead

NCT06831071Recruiting

Evaluation of Hypoxia in Primary Melanoma

Role: lead

NCT04658303Recruiting

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Role: lead

NCT03311308Phase 1Recruiting

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Role: lead

NCT02818023Phase 1Terminated

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Role: lead

NCT02339324Phase 1Completed

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Role: lead

All 8 trials loaded